Navigation Links
74 Percent EBITDA Improvement at Zeltia Group in 2010
Date:2/24/2011

MADRID, Feb. 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totaled 153.5 million euro in 2010 (approximately 211.4 million USD*), 24.4 percent more than in 2009 (123.4 million euro, or approximately 169.9 million USD). This performance is primarily attributable to a 70 percent increase in Yondelis® sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro (approximately 109.3 million USD) in 2010 (51.1 million euro, or approximately 70.3 million USD in 2009), of which 72.1 million (approximately 99.3 million USD) correspond to Yondelis® (43.8 million euro, or approximately 60.3 million USD in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro, or approximately 100.8 million USD in 2010, compared with 71.1 million euro, or approximately 97.9 million USD in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (approximately -5.3 million USD) (-15.3 million euro or approximately -21.0 million USD in 2009).

Net income attributable to the parent company rose 71 percent with respect to 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

This note is also available on the Zeltia web site: www.zeltia.com.

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3773.


'/>"/>
SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 34 percent of Galician secondary schools exceed maximum recommended radon levels
2. 34 percent of Galician secondary schools exceed maximum recommended radon levels
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. ReVisions Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
5. Tecnalia investigates ecological cement that cuts CO2 emissions by up to 100 percent
6. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
7. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
8. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
9. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
10. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
11. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):